Andra AP fonden Sells 11,400 Shares of Gilead Sciences, Inc. $GILD

Andra AP fonden reduced its holdings in shares of Gilead Sciences, Inc. (NASDAQ:GILD) by 5.1% during the second quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 211,201 shares of the biopharmaceutical company’s stock after selling 11,400 shares during the quarter. Andra AP fonden’s holdings in Gilead Sciences were worth $26,683,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other institutional investors have also recently made changes to their positions in GILD. BlackRock Inc. bought a new stake in shares of Gilead Sciences in the second quarter worth $15,393,785,000. State Street Corp lifted its stake in shares of Gilead Sciences by 2.3% in the 2nd quarter. State Street Corp now owns 61,216,552 shares of the biopharmaceutical company’s stock worth $7,734,099,000 after purchasing an additional 1,357,967 shares during the period. Norges Bank bought a new position in shares of Gilead Sciences in the 4th quarter worth approximately $2,617,152,000. Invesco Ltd. boosted its holdings in shares of Gilead Sciences by 2.9% in the fourth quarter. Invesco Ltd. now owns 15,584,341 shares of the biopharmaceutical company’s stock worth $1,912,822,000 after buying an additional 444,660 shares during the last quarter. Finally, Amundi grew its position in Gilead Sciences by 10.7% during the first quarter. Amundi now owns 10,539,111 shares of the biopharmaceutical company’s stock valued at $1,468,836,000 after buying an additional 1,018,976 shares during the period. Hedge funds and other institutional investors own 83.67% of the company’s stock.

Gilead Sciences Price Performance

Shares of GILD traded up $1.95 during midday trading on Tuesday, hitting $152.51. 1,473,908 shares of the company traded hands, compared to its average volume of 6,927,831. The stock has a market cap of $189.11 billion, a price-to-earnings ratio of -57.16 and a beta of 0.33. The firm has a 50 day moving average of $140.37 and a 200-day moving average of $136.24. The company has a debt-to-equity ratio of 2.03, a quick ratio of 1.09 and a current ratio of 1.27. Gilead Sciences, Inc. has a 52 week low of $108.46 and a 52 week high of $157.29.

Gilead Sciences (NASDAQ:GILD) last issued its earnings results on Monday, August 3rd. The biopharmaceutical company reported ($6.75) earnings per share (EPS) for the quarter, topping the consensus estimate of ($7.25) by $0.50. The firm had revenue of $7.80 billion for the quarter, compared to analysts’ expectations of $7.40 billion. Gilead Sciences had a negative return on equity of 2.11% and a negative net margin of 10.64%.The business’s revenue was up 10.6% compared to the same quarter last year. During the same period in the previous year, the firm posted $2.01 earnings per share. On average, analysts forecast that Gilead Sciences, Inc. will post -0.48 EPS for the current fiscal year.

Gilead Sciences Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Tuesday, September 29th. Shareholders of record on Tuesday, September 15th will be paid a $0.82 dividend. The ex-dividend date of this dividend is Tuesday, September 15th. This represents a $3.28 dividend on an annualized basis and a yield of 2.2%. Gilead Sciences’s payout ratio is presently -122.85%.

Analyst Ratings Changes

Several research firms have weighed in on GILD. Leerink Partners downgraded shares of Gilead Sciences from an “outperform” rating to a “market perform” rating and decreased their price target for the stock from $146.00 to $127.00 in a research report on Tuesday, July 21st. Morgan Stanley reduced their price objective on Gilead Sciences from $166.00 to $165.00 and set an “overweight” rating for the company in a research note on Monday, July 27th. Cantor Fitzgerald reaffirmed an “overweight” rating and issued a $155.00 target price on shares of Gilead Sciences in a report on Wednesday, August 5th. Needham & Company LLC reiterated a “buy” rating and set a $170.00 target price on shares of Gilead Sciences in a research report on Wednesday, August 5th. Finally, Royal Bank Of Canada boosted their price target on Gilead Sciences from $120.00 to $123.00 and gave the company a “sector perform” rating in a report on Wednesday, August 5th. One research analyst has rated the stock with a Strong Buy rating, twenty-three have given a Buy rating and five have issued a Hold rating to the company. According to data from MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus price target of $158.78.

Insider Buying and Selling at Gilead Sciences

In other news, Director Anthony Welters sold 18,000 shares of the stock in a transaction that occurred on Wednesday, August 26th. The stock was sold at an average price of $148.62, for a total transaction of $2,675,160.00. Following the completion of the transaction, the director directly owned 12,894 shares in the company, valued at approximately $1,916,306.28. This represents a 58.26% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Jeffrey Bluestone sold 5,000 shares of the firm’s stock in a transaction on Thursday, August 20th. The shares were sold at an average price of $145.02, for a total transaction of $725,100.00. Following the completion of the transaction, the director directly owned 10,066 shares of the company’s stock, valued at approximately $1,459,771.32. This trade represents a 33.19% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last ninety days, insiders sold 105,000 shares of company stock worth $14,616,390. Company insiders own 0.30% of the company’s stock.

Gilead Sciences Company Profile

Gilead Sciences, Inc is a biopharmaceutical company that discovers, develops and commercializes medicines for serious and life-threatening diseases. The company’s research focuses primarily on virology, oncology, inflammation and related areas, with products serving patients in the United States and international markets.

Gilead is best known for its HIV treatments, including Biktarvy, Genvoya, Descovy and other antiretroviral therapies. Its portfolio also includes medicines for viral hepatitis, such as Epclusa and Vemlidy, and Veklury (remdesivir), an antiviral treatment for COVID-19.